NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6714.00 3.50 (0.05%)

206.0K NSE+BSE Volume

NSE 11 May, 2026 3:31 PM (IST)

178,235.6

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

06 Apr 2026

6714.00

0.05%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The outlook remains positive, supported by Divi's strong positioning in custom synthesis and a diversified pipeline, with management highlighting active engagement with global innovator customers and multiple projects progressing through development and validation. Ongoing capacity additions along with a focus on disciplined execution and supply reliability are expected to support future growth, while the nutraceuticals business continues to provide healthy momentum and diversification. The company has also completed construction of a dedicated peptide facility, strengthening its capabilities in this fast-evolving segment, and...

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

20 Nov 2025

6714.00

0.05%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

10 Nov 2025

6714.00

0.05%

Divi's Labs (HOLD): Key molecule LOE to risk upside growth in Custom Synthesis

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 3%/9%/11% above estimates. EBITDA margin reported 170 bps above estimates.

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

10 Nov 2025

6714.00

0.05%

Divi's Laboratories (DIVI IN) Q2FY26 Result Update Peptides...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories .. has an average target of 6600.67 from 6 brokers.

Divi's Laboratories Ltd.

09 Nov 2025

6714.00

0.05%

Generics continue to drag growth, CS outlook unchanged

Sell: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.

Divi's Laboratories .. has an average target of 6600.67 from 6 brokers.

Divi's Laboratories Ltd.

08 Nov 2025

6714.00

0.05%

Operating leverage and CS strength support margins

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

10 Sep 2025

6714.00

0.05%

DIVI' S LAB

Sell: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The company's outlook remains positive due to growth drivers such as increased traction from global innovators, a healthy pipeline of RFPs, expansion of scientific and technological capabilities, and steady growth in the nutraceutical business. Management highlighted persistent pricing pressures in generics and higher cost escalation compared to custom synthesis, weighing on margins. Regulatory delays of 12-24 months for peptides, contrast media, and Kakinada approvals restricted near term revenue conversion. Divi's also faces the risk of losing business related to...

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

29 Aug 2025

6714.00

0.05%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

07 Aug 2025

6714.00

0.05%

Divi's Laboratories (DIVI IN) Q1FY26 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q1FY26 EBITDA was 4% below our estimates led by lower margins despite higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates stand marginally reduced by 3-4%. We expect 20% EBITDA CAGR and 12% PAT CAGR over FY25-27E. At CMP,...